Why HE4 May Offer Improved Specificity Compared to CA-125 in Premenopausal Women
Understanding HE4 and CA-125 ovarian biomarkers, the ROMA score, and how combined testing supports informed health decisions for premenopausal women.
When it comes to ovarian health screening, many women across London and the wider UK have heard of the CA-125 blood test. It has been a longstanding biomarker used in the assessment of ovarian conditions. However, emerging clinical evidence suggests that HE4 (Human Epididymis Protein 4) may often be a more specific blood marker than CA-125 in premenopausal women. Understanding why HE4 may offer improved specificity compared to CA-125 in premenopausal women can help individuals make more informed choices about their health screening options.
What Are HE4 and CA-125? A Quick Definition
HE4 (Human Epididymis Protein 4) is a glycoprotein biomarker measured through a simple blood test. It is primarily associated with certain ovarian cell types and may be elevated in the presence of ovarian abnormalities. CA-125 (Cancer Antigen 125) is a protein that can be found at higher levels in the blood when certain conditions — both benign and more serious — affect the ovaries or surrounding tissues.
Both markers are used as part of broader health assessments. Neither test alone provides a diagnosis; rather, each offers a piece of the wider clinical picture that an appropriate healthcare professional can interpret. For a deeper exploration of how these two markers work together, see our guide on why a combined CA-125 and HE4 approach may be more reliable.
Practical Insight: A single biomarker result is not a diagnosis. It is one data point that, when reviewed alongside medical history and other assessments, can help guide further investigation.
Why CA-125 Can Be Less Reliable in Premenopausal Women
CA-125 has been used for decades, and it remains a valuable tool in certain clinical contexts. However, in premenopausal women, CA-125 levels can be influenced by a wide range of benign conditions, which may lead to elevated readings that do not necessarily reflect serious ovarian pathology.
Common benign reasons for elevated CA-125 in premenopausal women include:
- Menstruation — CA-125 levels can naturally fluctuate during the menstrual cycle
- Endometriosis — a common condition that may significantly raise CA-125
- Uterine fibroids — benign growths that can sometimes influence CA-125 readings
- Pelvic inflammatory disease (PID) — infection or inflammation in the pelvic area
- Ovarian cysts — functional cysts that are often harmless
- Early pregnancy — hormonal changes may temporarily elevate CA-125
Practical Insight: An elevated CA-125 in a premenopausal woman does not necessarily indicate a serious condition. It may simply reflect normal physiological changes or common benign gynaecological conditions.
How HE4 Offers Improved Specificity
Research published in peer-reviewed journals, including studies referenced by the British Journal of Cancer and Gynecologic Oncology (e.g., Moore et al., 2012; Molina et al., 2011), suggests that HE4 tends to remain more stable in the presence of the benign conditions listed above. This means that HE4 may be less likely to produce false-positive results in premenopausal women compared to CA-125.
The key clinical advantage of HE4 lies in its potentially higher specificity — that is, its ability to more accurately distinguish between benign and potentially concerning ovarian changes. While CA-125 can be elevated by many non-serious conditions, HE4 levels are generally considered less affected by menstruation, endometriosis, and functional ovarian cysts based on published research to date.
HE4 vs CA-125: Comparison Table
| Feature | CA-125 | HE4 |
|---|---|---|
| Type | Glycoprotein biomarker | Glycoprotein biomarker |
| Affected by menstruation | Yes — levels may fluctuate | Generally not significantly affected |
| Affected by endometriosis | Yes — often elevated | Usually remains within expected range |
| Affected by ovarian cysts | Yes — can be raised | Less commonly affected |
| Specificity in premenopausal women | Lower — more false positives | Higher — fewer false positives |
| Used in ROMA score | Yes (combined with HE4) | Yes (combined with CA-125) |
| Standalone diagnostic value | Limited — requires clinical context | Limited — requires clinical context |
| Availability in UK private clinics | Widely available | Increasingly available |
Practical Insight: Neither biomarker replaces comprehensive clinical assessment. However, HE4 may offer a more reliable individual reading for premenopausal women due to its reduced sensitivity to benign gynaecological conditions.
What Is the ROMA Score and Why Does It Matter?
The Risk of Ovarian Malignancy Algorithm (ROMA) combines both HE4 and CA-125 results alongside menopausal status to generate a risk stratification score. This algorithm was developed to improve the accuracy of ovarian risk assessment by using both biomarkers together rather than relying on one alone.
For premenopausal women, the ROMA score calculation gives particular weight to HE4, reflecting the clinical understanding that HE4 provides more consistent data in this demographic.
If you are interested in understanding the range of blood tests available for women’s health, exploring both markers together may be worth considering.
Who Should Consider HE4 Testing?
HE4 testing may be particularly relevant for:
- Premenopausal women who want a biomarker less influenced by common gynaecological conditions
- Women with known endometriosis where CA-125 levels may already be chronically elevated
- Individuals with a family history of ovarian conditions who wish to monitor their baseline biomarker levels
- Women seeking proactive health screening as part of a broader wellness strategy. It is also worth understanding the differences between cervical and ovarian screening.
- Those who have previously received elevated CA-125 results attributed to benign causes and wish to explore an alternative marker
Testing is available at private health screening clinics across London and the UK. At Health Screening Clinic, we provide nurse-led blood testing and reporting services. For guidance on selecting the right panel, our women’s preventive screening guide offers practical advice.
Practical Insight: If you have previously had an elevated CA-125 result and were told the cause was likely benign, HE4 testing may offer additional reassurance as a complementary or alternative biomarker to monitor over time.
How Often Should You Test?
There is no single recommended frequency for HE4 or CA-125 testing that applies to everyone. The appropriate interval depends on personal and family medical history, previous biomarker results, age and menopausal status, and ongoing health monitoring plans agreed with a healthcare professional.
For many women using these tests as part of proactive health monitoring, annual or biannual testing may be considered. Incorporating ovarian biomarker testing into your annual health MOT can provide a more comprehensive picture of your overall wellbeing. Establishing a baseline reading and then tracking changes over time can sometimes be more informative than a single isolated result.
Understanding Your Results
When you receive HE4 or CA-125 results, it is important to understand that:
- Results within the expected range can provide reassurance, though they do not guarantee the absence of all conditions
- Results above the expected range do not automatically indicate a serious condition — further assessment by an appropriate healthcare professional is typically recommended
- Trends over time (rising, stable, or falling levels) can sometimes be more clinically meaningful than a single reading
At Health Screening Clinic, we provide clearly presented results with reference ranges. We always recommend discussing your results with a qualified healthcare professional who can interpret them within the context of your full medical history.
HE4 Testing in London: Accessible and Convenient
For women living and working in London, accessing private blood testing has become increasingly straightforward. Nurse-led clinics offer a convenient option for accessing biomarkers like HE4 that may not always be routinely available through standard NHS pathways.
Private health screening allows you to take a proactive approach to monitoring your wellbeing. Whether you are exploring cancer screening tests included in health checkups or broader health assessment packages, understanding your options is the first step.
Frequently Asked Questions
Why may HE4 offer improved specificity compared to CA-125 in premenopausal women?
HE4 tends to be less affected by common benign gynaecological conditions such as endometriosis, menstruation, and ovarian cysts. This means it may produce fewer false-positive results in premenopausal women, offering improved specificity when assessing ovarian biomarker levels.
Can HE4 replace CA-125 entirely?
HE4 is not typically considered a direct replacement for CA-125. Both biomarkers provide different but complementary information. In many clinical settings, they are used together — particularly within the ROMA algorithm — to offer a more comprehensive assessment.
Is the HE4 blood test available on the NHS?
HE4 testing may be available through NHS pathways in certain clinical circumstances, but it is not always routinely offered. Private health screening clinics in London and across the UK can provide HE4 testing as part of individual blood test requests.
What does a raised HE4 level mean?
An elevated HE4 level may suggest further investigation is warranted, but it does not constitute a diagnosis on its own. Results should always be interpreted by an appropriate healthcare professional alongside your medical history.
Should I have both HE4 and CA-125 tested together?
Having both markers tested together can sometimes provide a more complete picture, especially when used to calculate a ROMA score. This approach may be particularly useful for premenopausal women seeking a thorough baseline assessment.
How often should premenopausal women have HE4 testing?
There is no universal recommendation. Testing frequency should be guided by individual risk factors, family history, and advice from a healthcare professional. Annual or biannual monitoring may be appropriate for some women.
Does endometriosis affect HE4 levels?
Unlike CA-125, which is frequently elevated in women with endometriosis, HE4 levels are generally less influenced by this condition. This is one of the key reasons HE4 may be considered a more specific biomarker for premenopausal women.
Can I request HE4 testing without a referral?
Yes. At private health screening clinics such as Health Screening Clinic, you can request HE4 blood testing directly without the need for a referral. Results are provided for you to share with your healthcare provider.
Is HE4 testing suitable for postmenopausal women too?
Yes, HE4 can be used in postmenopausal women as well. However, the particular advantage of HE4 over CA-125 is most pronounced in premenopausal women, where CA-125 is more likely to be affected by benign conditions.
Take a Proactive Step Towards Understanding Your Health
Knowledge is one of the most empowering tools in managing your wellbeing. If you are considering ovarian biomarker testing, exploring the differences between HE4 and CA-125 is a valuable starting point. Visit Health Screening Clinic to learn more about the blood tests we offer and how our nurse-led service can support your health monitoring journey.
Disclaimer
This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. The information provided should not be used as a substitute for professional medical guidance. Individual symptoms, health concerns, or blood test results should always be assessed and interpreted by an appropriate healthcare professional. Health Screening Clinic provides testing and reporting services only and does not offer diagnoses, prescriptions, or treatment. Treatment suitability and testing frequency depend on individual clinical assessment. No guarantees regarding health outcomes are made or implied within this content.
